前列腺特异性膜抗原PET/CT引导的转移灶定向放疗用于寡转移性去势抵抗性前列腺癌
该研究回顾性筛选5项前瞻性PSMA PET/CT研究,纳入24例在PSMA PET/CT上最多5处寡复发或寡进展病灶的mCRPC患者,接受对所有新发或进展病灶的根治意向转移灶定向放疗并同步雄激素剥夺治疗。中位随访33.8个月,中位无进展生存期16.4个月,生化反应率66.7%,2年和4年总生存率分别为91.1%和68.8%,2级毒性率4.2%,3级及以上毒性率0%。作者认为该方案似可提供持久疾病控制且毒性低,需进一步前瞻性研究比较转移灶定向放疗联合全身治疗与单纯全身治疗、以及PSMA PET/CT引导与传统影像引导放疗。
要点
- 在最多5处寡转移mCRPC患者中,PSMA PET/CT引导转移灶定向放疗的中位无进展生存期为16.4个月。
- 2级毒性率为4.2%,3级及以上毒性率为0%。
- 作者认为需进一步前瞻性研究比较该方案与单纯全身治疗及不同影像引导方式。
核心结论
- PSMA PET/CT引导的转移灶定向放疗似可为寡转移性去势抵抗性前列腺癌提供持久疾病控制且毒性率低。
- 作者认为需进一步前瞻性研究比较转移灶定向放疗联合全身治疗与单纯全身治疗,以及PSMA PET/CT引导与传统影像引导放疗。
研究设计与样本
- 回顾性筛选5项前瞻性PSMA PET/CT研究,纳入PSMA PET/CT上最多5处寡复发或寡进展病灶的mCRPC患者。
- 患者接受对所有新发或进展病灶的根治意向转移灶定向放疗并同步雄激素剥夺治疗。
- 采用Kaplan-Meier分析计算无进展生存期、无新全身治疗生存期和总生存期。
- 生化反应定义为治疗开始后6个月前列腺特异性抗原下降至少50%。
- 毒性采用不良事件通用术语标准第5版分级。
主要发现
- 共24例患者符合纳入标准,中位随访33.8个月(四分位距27.6-45.1个月)。
- 2017年10月至2023年4月间,11例(45.8%)治疗1处病灶,10例(41.7%)治疗2处,3例(12.5%)治疗3处。
- 治疗部位中前列腺或前列腺床5处、淋巴结15处、骨19处、内脏1处。
- 17例(70.8%)继续原有全身治疗,7例(29.2%)开始新的全身治疗。
- 中位无进展生存期16.4个月(95%CI 9.8-23.0个月),生化反应率66.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需进一步前瞻性研究比较转移灶定向放疗联合全身治疗与单纯全身治疗,以及PSMA PET/CT引导与传统影像引导放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic treatments for metastatic castration-resistant prostate cancer (mCRPC) include androgen deprivation therapy, androgen receptor pathway inhibitors, chemotherapy, and radiopharmaceuticals, all of which have associated toxicity. Prostate-specific membrane antigen (PSMA) PET/CT allows for higher sensitivity in detecting metastatic disease than is possible with conventional imaging. We hypothesized that PSMA PET/CT-guided, metastasis-directed radiotherapy may offer durable disease control with low toxicity rates in patients with mCRPC who have a limited number of metastases. Methods: We retrospectively screened 5 prospective PSMA PET/CT studies for patients with mCRPC who had up to 5 sites of oligorecurrent or oligoprogressive disease on PSMA PET/CT and subsequently received definitive-intent, metastasis-directed radiotherapy to all new or progressing sites with concurrent androgen deprivation therapy. Progression-free survival, freedom from new lines of systemic therapy, and overall survival (OS) were calculated from the start of metastasis-directed radiotherapy using Kaplan-Meier analysis. Biochemical response was defined as at least a 50% decrease in prostate-specific antigen 6 mo after the start of treatment. Toxicity was graded using the Common Terminology Criteria for Adverse Events, version 5. Results: Twenty-four patients met the inclusion criteria with a median follow-up of 33.8 mo (interquartile range, 27.6-45.1 mo). Between October 2017 and April 2023, 11 patients (45.8%) had 1 treated site, 10 patients (41.7%) had 2, and 3 patients (12.5%) had 3. Five sites were prostate or prostate bed, 15 were nodal, 19 were osseous, and 1 was visceral. Seventeen patients (70.8%) continued their preexisting systemic therapy, whereas 7 (29.2%) started a new systemic therapy. Median progression-free survival was 16.4 mo (95% CI, 9.8-23.0 mo). The biochemical response rate was 66.7%. Median freedom from a new line of systemic therapy was 29.0 mo (95% CI, 7.6-50.4 mo). Median OS was not reached. The 2- and 4-y OS rates were 91.1% (95% CI, 79.3%-100%) and 68.8% (95% CI, 45.1%-92.5%), respectively. Grade 2 and grade 3 or higher toxicity rates were 4.2% and 0%, respectively. Conclusion: PSMA PET/CT-guided, metastasis-directed radiotherapy appears to offer durable disease control with low toxicity rates for oligometastatic castration-resistant prostate cancer. Further prospective studies are needed to compare metastasis-directed radiotherapy with systemic therapy versus systemic therapy alone and PSMA PET/CT-guided versus conventional imaging-guided radiotherapy.
引用
- Nikitas J, Castellanos Rieger A, Farolfi A, et al. Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024. PMID: 39089811. doi:10.2967/jnumed.124.267922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。